Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a report issued on Saturday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
斯托克新聞網的投資分析師在週六發佈的一份報告中對Otmey(納斯達克:One-Get Rating)的股票進行了報道。該經紀公司對這家生物製藥公司的股票設定了“持有”評級。
Separately, Piper Sandler cut shares of Otonomy from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $3.00 to $0.50 in a research report on Thursday, October 13th.
另外,在10月13日星期四的一份研究報告中,派珀·桑德勒將Otmey的股票評級從增持下調至中性,並將該公司的目標價從3.00美元下調至0.50美元。
Otonomy Price Performance
高性價比
NASDAQ:OTIC opened at $0.08 on Friday. The firm has a 50-day moving average of $0.11 and a two-hundred day moving average of $0.71. The stock has a market cap of $4.40 million, a P/E ratio of -0.10 and a beta of 1.31. Otonomy has a 1-year low of $0.06 and a 1-year high of $2.59.
納斯達克:週五開盤報0.08美元。該公司的50日移動均線切入位在0.11美元,200日移動均線切入位在0.71美元。該股市值為440萬美元,本益比為-0.10,貝塔係數為1.31。Otomy的一年低點為0.06美元,一年高位為2.59美元。
Institutional Investors Weigh In On Otonomy
機構投資者在Otmey上發表看法
About Otonomy
關於Otomy
(Get Rating)
(獲取評級)
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.
Otomy,Inc.是一家生物製藥公司,在美國開發神經學療法。該公司提供治療耳鳴的N-甲基-D-天冬氨酸受體拮抗劑Gacycldine的持續暴露製劑OTO-313,以及治療耳鳴的腦源性神經營養因數持續暴露製劑OTO-413,該製劑處於第二階段臨床試驗,用於修復耳蝸突觸和治療噪音中語音聽力困難。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取StockNews.com關於OTMy的研究報告(OTIC)
- MarketBeat:回顧一週12/19-12/23
- 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
- 通脹降溫,標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收《Otmey Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Otmey及相關公司評級的每日簡要摘要。